Meet our leadership team – who between them – have a deep knowledge of and long track records in the biotech and pharmaceutical industries.
Chris has a unique background of scientific and business experience being awarded a PhD in Cell Biology from the University of Manchester before developing and leading successful customer-centric sales teams in the pharmacology CRO sector.
Chris is passionate about improving the therapeutic options available for cancer patients and enabling the scientists that carry out this important work to achieve their goals.
Nicki originally qualified with PWC and has over 20 years experience as CFO for several PE backed, fast growth healthcare and technology businesses. She has taken companies from start-up to exit and has secured numerous funding rounds including equity, bank and venture debt. At Imagen she is responsible for leading financial strategy, accounting, control and compliance.
Nicki’s goal is to support Imagen’s growth and vision to accelerate drug discovery and the development of new cancer therapies to enhance patient lives.
Jonathan is a successful entrepreneur with a proven ability to develop, scale and sell companies in the medical field. He leads the board and is a present and integral member of the leadership team. After the successful growth and sale of Clinphone.
Jonathan invested in Imagen, with the ambition of working with Gareth to develop an in vitro system that could help oncologists select the right treatments for their patients.
Gareth co-founded Imagen following senior scientific roles in AstraZeneca, with the vision of developing an accurate method of modelling cancer tumour in the lab. He is an innovator in his field having developed and patented various assay development methods and is a respected expert in cell biology.
Gareth is passionate about translating science into outcomes for patients and is responsible for leading the scientific strategy and implementation at Imagen.
Dominic has over 30 years’ experience in molecular and cellular biology with roles at the European Molecular Biology Laboratory, University of Geneva and Cancer Research UK. He has successfully led drug discovery projects for CRUK from target identification through to licencing. Dominic is an enthusiastic and highly skilled scientist who was recently elected as a Fellow to the Royal Society of Biology.
Richard Goldstein graduated from the University of Cambridge with a degree in Law in 1983. Following a period of practice as an M&A lawyer at a leading law firm, and then as Legal Counsel at Superdrug Stores PLC, he obtained an MBA with Distinction from INSEAD in France in 1990, before leading the buy-in, and subsequently the management, of Harding Brothers Limited, now the second-largest operator of retail environments on board luxury cruise ships. Richard now operates and manages the investment activities of a family investment office, and sits on the Board of a number of companies in which he is also involved as an investor, including Imagen.
Together with Jonathan, Neil founded Clinphone. The business went through private equity funding via Montagu/Hg to grow the business and successfully exit via float in 2006.
Neil is medically qualified and is a serial pharma entrepreneur, most recently he exited Cmed Group and Exco In Touch.
He is currently NED at Greenphire, a global clinical trial payment technology business.
